Stock Financial Ratios, Dividends, Split History
WAIR / Wesco Aircraft Holdings Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||1,020.05|
|Enterprise Value ($M)||1,961.71|
|Book Value ($M)||672.09|
|Book Value / Share||6.76|
|Price / Book||1.56|
|NCAV / Share||0.91|
|Price / NCAV||12.67|
|Weighted Average Number Of Diluted Shares Outstanding||98,700,879|
|Common Shares Outstanding||99,433,767|
|Common Stock Shares Outstanding||99,450,902|
|Preferred Stock Shares Outstanding||0|
|Weighted Average Number Of Shares Outstanding Basic||98,700,879|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||n/a|
|Return on Assets (ROA)||n/a|
|Return on Equity (ROE)||n/a|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1378718|
|SIC 5072 - Hardware|
Stock splits are used by Wesco Aircraft Holdings Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Related News Stories
Per major media sources, The Boeing Company (BA - Free Report) recently secured a $6.6 billion contract for delivering 24 cargo aircraft to FedEx Express, which is a subsidiary of Tennessee-based FedEx courier delivery services company. Per the terms, FedEx has ordered 12 of Boeing’s 767 freighter aircraft and 12 of the twin aisle large-sized 777 cargo aircraft. With the latest deal inked, Boeing has further strengthened its relationship with FedEx, one of its major cargo customers for nearly 41 years now. (62-0)
Lockheed Martin Corp.’s (LMT - Free Report) Aeronautics division recently won a $503.2 million modification contract for providing air vehicle initial spare parts in support of the F-35 program. The contract was awarded by the Naval Air Systems Command, Patuxent River, MD. Details of the Deal Per the deal, Lockheed Martin will provide initial spares that include F-35 Lightning II deployment spares packages, afloat spares packages and associated consumables. (22-0)
Textron Inc.’s (TXT - Free Report) Aviation Defense business unit recently secured a $36.2 million modification contract related to T-6C aircraft. The deal is scheduled to be completed by Nov 30, 2018. (20-0)
The Boeing Company (BA - Free Report) recently won a contract for procuring system configuration set H12K to support Kuwait government’s fleet of F/A-18E/F Aircraft. Work related to the deal is scheduled to be completed by September 2022. (62-0)
The Boeing Company (BA - Free Report) recently won a $1.52 billion contract to provide system configuration sets and associated services for life-cycle upgrading of the F/A-18A/B, C/D, E/F and EA-18G aircraft. The deal will cater to the U.S. Navy and foreign military sales (FMS) customers. Details of the Deal Per the terms, Boeing will provide deliverables and services including FMS unique system configuration sets, system improvement and demonstration products, laboratory upgrades, and studies and analysis. (63-0)
as of ET